ArticleTranslational cancer research2026
Pan-cancer analysis reveals FOLH1 as a prognostic biomarker and immune modulator in human tumors.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Folate hydrolase-1 (FOLH1) is the gene encoding prostate-specific membrane antigen (PSMA) and is highly associated with prostate cancer. However, its involvement in other tumorigenesis remains to be investigated. This study aims to elucidate its role in multiple cancers through various bioinformatics approaches. Methods: In this study, we integrated the multi-omics data of TCGA (The Cancer Genome Atlas Program), GTEx (The Genotype-Tissue Expression), and CPTAC (Clinical Proteomic Tumor Analysis Consortium) to analyze the expression pattern, genetic variation, copy number alteration (CNA), and methylation characteristics of FOLH1 in 33 cancers by using tools such as TIMER 2.0, GEPIA 3, and cBioPortal. We also assessed its prognostic significance by survival analysis and combined the immune infiltration algorithm with the drug sensitivity database to reveal its relationship with the tumor microenvironment, including immune checkpoints, tumor mutation burden (TMB), microsatellite instability (MSI), and chemotherapy response. Results: FOLH1 expression was significantly up-regulated in uterine corpus endometrial carcinoma (UCEC), adrenocortical carcinoma (ACC), and colon adenocarcinoma (COAD), and low in breast invasive carcinoma (BRCA) and liver hepatocellular carcinoma (LIHC). Survival analysis showed that high FOLH1 expression was significantly associated with shorter overall survival (OS) in patients with ACC and pancreatic adenocarcinoma (PAAD), but showed the opposite trend in stomach adenocarcinoma (STAD). Conclusions: FOLH1 may be involved in tumor progression by regulating amino acid metabolic pathways and the immune microenvironment. It is a promising pan-cancer prognostic marker and synergistic target for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.